Eli Lilly, telehealth firm team up to expand Zepbound access

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound.

Advertisement

Through Ro’s platform, eligible patients can receive prescriptions during telehealth visits and have the medication shipped directly to their homes. 

This integration with LillyDirect, Lilly’s direct-to-consumer platform, allows patients to pay out of pocket for the medication. The 2.5-milligram and 5-milligram vials are priced at $399 and $549, respectively, for a four-week supply.

LillyDirect also offers home delivery services for Zepbound through Gifthealth, a third-party digital pharmacy, according to CNBC.

Interested in sharing your own thoughts? Take this quick survey about how your system is approaching GLP-1 medications here.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

How Leading Pharmacies Stay Stocked And Protect Margins

Thursday, July 23
12:00 PM - 1:00 PM CDT

Presenters: Calvin Hunsicker, SureCostChad O’Connor, SureCost

Advertisement

Next Up in GLP-1s

Advertisement

Comments are closed.